A study of bleeding time in 120 long-term aspirin trial patients.
The bleeding time was measured in 120 patients participating in a longterm randomised double-blind trial of aspirin in thromboembolic prophylaxis (UK-TIA aspirin Study). In 70 patients taking aspirin 300 mg or 1,200 mg daily for a mean duration of 35 months the bleeding time averaged 228 seconds. In comparison with 30 patients randomised to placebo and not taking aspirin whose bleeding time averaged 217 seconds, there was no significant difference. Stratification of bleeding time estimation by duration of treatment suggested no significant trend in either placebo or aspirin groups over several years. These results suggest that the longterm trials of aspirin should be looked at again from the point of view of efficacy of treatment by time from randomisation.
Frith
P A
PA
Department of Clinical Neurology, Radcliffe Infirmary, Oxford, U.K.
Warlow
C P
CP
D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D001760:Bleeding Time; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011897:Random Allocation; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
D001241:Aspirin